# Patient and Healthcare Provider Perspectives on the Path to Diagnosis of Seborrheic Dermatitis: Results From a National Survey of Adults With Seborrheic Dermatitis in the United States

## Raj Chovatiya,<sup>1</sup> Lakshi Aldredge,<sup>2</sup> Candrice Heath,<sup>3</sup> Moises Acevedo,<sup>4</sup> David Chu,<sup>5</sup> Diane Hanna,<sup>5</sup> Melissa Seal,<sup>5</sup> Matthew Zirwas<sup>6</sup>

<sup>1</sup>Northwestern University, Chicago, IL, USA; <sup>2</sup>Veterans Administration Portland Health Care System, Portland, OR, USA; <sup>3</sup>Temple University, Philadelphia, PA, USA; <sup>4</sup> Park Plaza Dermatology, New York, NY, USA; <sup>5</sup>Arcutis Biotherapeutics, Westlake Village, CA, USA; <sup>6</sup>Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA

## INTRODUCTION

- Seborrheic dermatitis (SD) is a common chronic inflammatory skin disease with a worldwide prevalence of up to 5%<sup>1</sup>; however, little is known about patient and provider views, preferences, impressions, and path to diagnosis of SD
- The authors developed an online survey, conducted by the Harris Poll, on burden, experiences, and preferences of patients with SD and healthcare providers (HCPs)
- This poster presents the results related to the path to diagnosis of SD

## METHODS

- The patient survey was conducted online from December 2021 through January 2022 among US adults diagnosed with SD by an HCP (Figure 1)
- Figures for age, sex, education, race/ethnicity, region, income, household size, and marital status were weighted where necessary to bring the data into line with actual proportions in the population
- Self-identified Black/African American patients were adjusted to natural fall out among the qualified patients
- A propensity score variable was also included to adjust for respondents' propensity to be online
- The HCP survey was conducted online from December 2021 through January 2022 by HCPs specializing in dermatology (including dermatologists, nurse practitioners [NPs], and physician assistants [PAs]) who see  $\geq 1$  patient per week and  $\geq 1$  patient with SD per year (Figure 2)
- For dermatologists, figures for years in practice, gender, and region were weighted where necessary to bring the data into line with actual proportions in the population
- For NP/PAs, raw data were not weighted and are therefore only representative of the individuals who completed the survey







HCP: healthcare provider; NP/PA: nurse practitioner/physician assistant; SD: seborrheic dermatitis

## RESULTS

- symptoms within 1 year (Figure 3)



- (91%)

• HCPs underestimated the time it takes for patients experiencing SD symptoms to seek care, with HCPs reporting an average of 1.6 years from symptom onset to diagnosis while patients reported an average of 3.6 years (Figure 3)

• A higher percentage of patients with severe disease reported visiting an HCP for their

• Before diagnosis, 56% of patients said it was hard to find information online about SD and 71% said they had not heard of SD prior to diagnosis(**Figure 4**)

- 86% of HCPs said that most patients had not heard of SD prior to their diagnosis • Most (83%) patients did not realize all their symptoms were due to SD and 76% mistook their symptoms for another skin condition (Figure 4)

 Most HCPs agreed that patients did not realize all their symptoms were due to SD (96%) and thought they mistook their symptoms for another skin condition

• Almost all (90%) patients wished they had known that there were specific symptoms to identify SD (**Figure 4**), with 85% of HCPs agreeing that their patients feel similarly



1. Dessinioti C, Katsambas A. Clin Dermatol 2013;31:343–351.

### ACKNOWLEDGEMENTS

- This study was supported by Arcutis Biotherapeutics, Inc
- Thank you to the investigators and their staff for their participation in the trial
- We are grateful to the study participants and their families for their time and commitment
- Writing support was provided by Lauren Ramsey, PharmD, Alligent Biopharm Consulting LLC, and funded by Arcutis Biotherapeutics, Inc.

### DISCLOSURES

RC, LA, CH, MA, and MZ are investigators and/or consultants for Arcutis Biotherapeutics, Inc. and received grants/research funding and/or honoraria; **DC**, **DH**, and **MS** are employees of Arcutis Biotherapeutics, Inc. Additional disclosures provided on request.



• HCPs underestimated the time it takes for patients experiencing SD symptoms to reach out, with a 2-year difference between what HCPs thought and patients reported • These findings reveal major needs in optimization of diagnosis, management, and

education for SD • Future studies are needed to better characterize and address these burdens